Lily Center for Biotechnology in San Diego, California, on March 1, 2023.
Mike Blake Reuters
On Thursday, Eli Lily informed mixed results for the fourth quarter, as sales of losing weight in weight and diabetes increased, but witnessed a decrease in the achieved prices.
The numbers were consistent with the initial results that Elie Lily participated in January, which was disappointed. Elie Lily cut her revenue instructions for 2024, saying that the demand for weight loss and diabetes would not fulfill her noble expectations.
The company’s quarterly profits topped the Wall Street estimates, but sales were short.
The giant pharmaceutical company has also issued financial profit directions 2025 from 22.05 dollars to $ 23.55 per share, which is in line with what analysts expect. Eli Lily launched her financial sales directives 2025 from $ 58 billion to $ 61 billion.
Here is what Elie Lily told for the fourth quarter compared to what Wall Street expected, based on a survey of analysts by LSEG:
- Arrow’s profits: 5.32 average $ 4.95 expected
- profit: 13.53 billion dollars compared to 13.57 billion dollars expected
The company recorded the fourth -quarter revenues of $ 13.53 billion, an increase of 45 % over the same period.
The pharmaceutical giant of the net income of $ 4.41 billion, or $ 4.88 per share, for the fourth quarter. This compares with a profit of $ 2.19 billion, or $ 2.42 per share, a year ago.
With the exception of the one -time items related to the value of unfinished assets and other assessments, El Lilly has published $ 5.32 per share per share for the fourth quarter of 2024.
This story is developing. Please check again for updates.
